Organon & Co. (OGN) to Release Earnings on Thursday

Organon & Co. (NYSE:OGN) is expected to release its earnings data before the market opens on Thursday, February 13th. Analysts expect Organon & Co. to post earnings of $0.92 per share and revenue of $1.59 billion for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Organon & Co. Stock Performance

Shares of NYSE OGN opened at $15.04 on Tuesday. The firm has a market cap of $3.87 billion, a price-to-earnings ratio of 2.98, a P/E/G ratio of 0.83 and a beta of 0.76. The business’s 50-day simple moving average is $15.35 and its 200-day simple moving average is $17.61. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Wall Street Analyst Weigh In

Separately, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $21.33.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.